[go: up one dir, main page]

AP2362A - Heteroaromatic quinoline compounds and their use as PDE10 inhibitors. - Google Patents

Heteroaromatic quinoline compounds and their use as PDE10 inhibitors.

Info

Publication number
AP2362A
AP2362A AP2007004043A AP2007004043A AP2362A AP 2362 A AP2362 A AP 2362A AP 2007004043 A AP2007004043 A AP 2007004043A AP 2007004043 A AP2007004043 A AP 2007004043A AP 2362 A AP2362 A AP 2362A
Authority
AP
ARIPO
Prior art keywords
quinoline compounds
pde10 inhibitors
heteroaromatic quinoline
heteroaromatic
pde10
Prior art date
Application number
AP2007004043A
Other languages
English (en)
Other versions
AP2007004043A0 (en
Inventor
Christopher John Helal
Denis Jay Hoover
Patrick Robert Verhoest
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2007004043A0 publication Critical patent/AP2007004043A0/xx
Application granted granted Critical
Publication of AP2362A publication Critical patent/AP2362A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2007004043A 2005-01-07 2005-12-22 Heteroaromatic quinoline compounds and their use as PDE10 inhibitors. AP2362A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64205805P 2005-01-07 2005-01-07

Publications (2)

Publication Number Publication Date
AP2007004043A0 AP2007004043A0 (en) 2007-06-30
AP2362A true AP2362A (en) 2012-02-08

Family

ID=36589327

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004043A AP2362A (en) 2005-01-07 2005-12-22 Heteroaromatic quinoline compounds and their use as PDE10 inhibitors.

Country Status (43)

Country Link
US (2) US7429665B2 (es)
EP (1) EP1841757B1 (es)
JP (1) JP4302762B2 (es)
KR (1) KR100896380B1 (es)
CN (2) CN101098866A (es)
AP (1) AP2362A (es)
AR (1) AR052863A1 (es)
AT (1) ATE472543T1 (es)
AU (1) AU2005323794B2 (es)
BR (1) BRPI0518508A2 (es)
CA (1) CA2592986C (es)
CR (1) CR9180A (es)
CU (1) CU23780B7 (es)
CY (1) CY1110746T1 (es)
DE (1) DE602005022115D1 (es)
DK (1) DK1841757T3 (es)
EA (1) EA012211B1 (es)
EG (1) EG25993A (es)
ES (1) ES2346674T3 (es)
GE (1) GEP20094623B (es)
GT (1) GT200600002A (es)
HN (1) HN2006000668A (es)
HR (1) HRP20100461T1 (es)
IL (1) IL183851A (es)
MA (1) MA29140B1 (es)
ME (1) ME01142B (es)
MX (1) MX2007008287A (es)
MY (1) MY142052A (es)
NL (1) NL1030863C2 (es)
NO (1) NO340476B1 (es)
NZ (1) NZ555737A (es)
PE (1) PE20060873A1 (es)
PL (1) PL1841757T3 (es)
PT (1) PT1841757E (es)
RS (1) RS51385B (es)
SI (1) SI1841757T1 (es)
SV (1) SV2008002365A (es)
TN (1) TNSN07258A1 (es)
TW (1) TWI312682B (es)
UA (1) UA86283C2 (es)
UY (1) UY29324A1 (es)
WO (1) WO2006072828A2 (es)
ZA (1) ZA200705427B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279548A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
ES2360014T3 (es) * 2006-12-21 2011-05-31 Pfizer Products Inc. Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina.
EA201000113A1 (ru) * 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
KR20110031355A (ko) 2008-06-25 2011-03-25 엔비보 파마슈티칼즈, 인코퍼레이티드 １,２―이치환된 헤테로사이클릭 화합물
RU2506260C2 (ru) * 2008-06-25 2014-02-10 Энвиво Фармасьютикалз, Инк. 1,2-дизамещенные гетероциклические соединения
ES2561181T3 (es) 2009-02-05 2016-02-24 Takeda Pharmaceutical Company Limited Compuestos de piridazinona
US20110305637A1 (en) 2009-02-24 2011-12-15 Janssen Pharmaceutica N.V. Radiolabelled pde10 ligands
ES2547124T3 (es) 2009-04-02 2015-10-01 Merck Patent Gmbh Inhibidores de autotaxina
HUE026238T2 (en) * 2009-05-07 2016-06-28 Forum Pharmaceuticals Inc Phenoxymethyl heterocyclic compounds
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AU2010311493B2 (en) * 2009-10-30 2014-06-05 Janssen Pharmaceutica Nv Radiolabelled PDE10 ligands
BR112012021198B1 (pt) 2010-02-26 2021-12-14 Mitsubishi Tanabe Pharma Corporation Compostos de pirazolopirimidina, composições relacionadas e seu uso como inibidores de pde10
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
AU2011270994B2 (en) 2010-06-24 2015-12-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
EP2602255B1 (en) 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012020780A1 (ja) 2010-08-10 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
UA106692C2 (uk) 2011-02-23 2014-09-25 Пфайзер Інк. ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
WO2012125598A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
JP5973990B2 (ja) 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
CN103596956A (zh) 2011-06-07 2014-02-19 辉瑞大药厂 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途
US9139567B2 (en) 2011-07-19 2015-09-22 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
ME02419B (me) 2011-08-25 2016-09-20 Merck Sharp & Dohme Inhibitori pirimidina pde10
WO2013045607A1 (en) * 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
CN103159738B (zh) * 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9138494B2 (en) * 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
NZ628587A (en) 2012-03-06 2016-07-29 Boehringer Ingelheim Int Benzodioxanes in combination with other actives for inhibiting leukotriene production
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
EP2841070B1 (en) * 2012-04-24 2018-07-25 Board Of Trustees Of Northern Illinois University Design and synthesis of novel inhibitors of isoprenoid biosynthesis
WO2014014874A1 (en) 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
AU2014221799B2 (en) 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
WO2014140184A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) * 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
JP2016523982A (ja) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9556150B2 (en) 2013-12-13 2017-01-31 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
EP3856185A1 (en) 2018-09-28 2021-08-04 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
TW202031250A (zh) 2018-11-06 2020-09-01 丹麥商Ｈ 朗德貝克公司 用於治療負性症狀和認知損傷之pde10a抑制劑
CN109384766B (zh) * 2018-11-19 2021-02-09 广东环境保护工程职业学院 一种喹啉类化合物及其制备方法和应用
CN109627232B (zh) * 2018-11-19 2021-02-09 广东环境保护工程职业学院 一种喹啉类化合物及其制备方法和应用
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113784713A (zh) * 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 白三烯合成抑制剂
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
GB202110990D0 (en) * 2021-07-30 2021-09-15 Benevolentai Cambridge Ltd Organic compound and their uses
EP4426284A4 (en) 2021-11-01 2025-11-12 Alkahest Inc Benzodioxane Leukotriene A4 Hydrolase (LTA4H) Modulators for the Prevention and Treatment of Age-Related Diseases
CN113956436B (zh) * 2021-11-09 2023-05-30 万华化学（宁波）有限公司 一种浅色且存储过程中色号稳定的二苯基甲烷二异氰酸酯组合物
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物
CN116731017B (zh) * 2023-06-02 2024-10-01 海南大学 一种喹啉并哌啶类化合物及其制备方法与应用
CN118255747A (zh) * 2024-03-08 2024-06-28 中山大学 一种3-三氟甲基取代的吡唑类化合物或其药学上可接受的盐及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000269A2 (de) * 2001-06-22 2003-01-03 Bayer Aktiengesellschaft Neue verwendung für pde 10a-inhibitoren
WO2003093499A2 (en) * 2002-05-03 2003-11-13 Pfizer Products Inc. Therapeutic use of selective pde10 inhibitors
WO2005120514A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE392582B (sv) * 1970-05-21 1977-04-04 Gore & Ass Forfarande vid framstellning av ett porost material, genom expandering och streckning av en tetrafluoretenpolymer framstelld i ett pastabildande strengsprutningsforfarande
US4340480A (en) * 1978-05-15 1982-07-20 Pall Corporation Process for preparing liquophilic polyamide membrane filter media and product
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
US5627079A (en) * 1989-03-27 1997-05-06 The Research Foundation Of State University Of New York Refunctionalized oxyfluorinated surfaces
US5270193A (en) * 1989-10-27 1993-12-14 E. I. Dupont De Nemours And Company Immobilization of biomolecules on perfluorocarbon surfaces
DE69017197T2 (de) * 1990-05-18 1995-09-14 Japan Gore Tex Inc Hydrophile poröse Membrane aus Fluoropolymer.
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9202633D0 (en) * 1992-02-07 1992-03-25 Fujisawa Pharmaceutical Co Heterocyclic derivatives
ATE264323T1 (de) * 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
DE4238389A1 (de) * 1992-11-13 1994-05-19 Bayer Ag Verfahren zur Durchführung immundiagnostischer Nachweise
US5614099A (en) * 1994-12-22 1997-03-25 Nitto Denko Corporation Highly permeable composite reverse osmosis membrane, method of producing the same, and method of using the same
US6207369B1 (en) * 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US5843789A (en) * 1995-05-16 1998-12-01 Neomecs Incorporated Method of analysis of genomic biopolymer and porous materials for genomic analyses
AU6854696A (en) * 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5914182A (en) * 1996-06-03 1999-06-22 Gore Hybrid Technologies, Inc. Materials and methods for the immobilization of bioactive species onto polymeric substrates
US5843958A (en) * 1996-11-27 1998-12-01 Ortho Pharmaceutical Corporation Arylpyrazoles as leukotriene inhibitors
US6342292B1 (en) * 1997-12-16 2002-01-29 Asahi Kasei Kabushiki Kaisha Organic thin film and process for producing the same
US6451396B1 (en) * 1998-02-13 2002-09-17 Gore Enterprise Holdings, Inc. Flexure endurant composite elastomer compositions
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6994972B2 (en) * 1999-09-02 2006-02-07 Corning Incorporated Porous substrates for DNA arrays
US6750023B2 (en) * 1999-09-02 2004-06-15 Corning Incorporated Porous inorganic substrate for high-density arrays
US6790613B1 (en) * 1999-11-12 2004-09-14 Amersham Biosciences Ab Method of preparing an oligonucleotide array
JP2001226650A (ja) * 2000-02-16 2001-08-21 Nitto Denko Corp 放射線硬化型熱剥離性粘着シート、及びこれを用いた切断片の製造方法
EP1297340A2 (en) * 2000-07-05 2003-04-02 Cuno Incorporated Low fluorescence nylon/glass composites for microdagnostics
US20030219816A1 (en) * 2001-07-02 2003-11-27 Keith Solomon Composite microarray slides
BR0106975A (pt) * 2000-07-06 2004-08-10 Cuno Inc Método de fabricação de um substrato cellular e substrato celular
TW513485B (en) * 2000-07-10 2002-12-11 Ind Tech Res Inst On-spot hydrophilic enhanced slide and preparation thereof
US6977155B2 (en) * 2000-08-10 2005-12-20 Corning Incorporated Arrays of biological membranes and methods and use thereof
EP1184349A1 (en) * 2000-09-01 2002-03-06 A.S.B.L. Facultes Universitaires Notre-Dame De La Paix Method for obtaining a surface activation of a solid support for building biochips microarrays
JP2002153272A (ja) * 2000-11-24 2002-05-28 Inst Of Physical & Chemical Res 生体分子マイクロアレイ
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6844028B2 (en) * 2001-06-26 2005-01-18 Accelr8 Technology Corporation Functional surface coating
US7054862B2 (en) * 2001-06-29 2006-05-30 International Business Machines Corporation Method and system for long-term update and edit control in a database system
FR2826957B1 (fr) * 2001-07-09 2005-09-30 Centre Nat Rech Scient Procede de fonctionnalisation de supports solides, supports solides fonctionnalises et leurs utilisations
WO2003014115A1 (en) 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
US20030068621A1 (en) * 2001-10-04 2003-04-10 Jonathan Briggs Method and device for producing oligonucleotide arrays
JP3884995B2 (ja) * 2002-05-29 2007-02-21 日東電工株式会社 皮膚貼着用粘着シート
US7332273B2 (en) * 2002-06-20 2008-02-19 Affymetrix, Inc. Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays
CA2493854A1 (en) * 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
JP2004072743A (ja) * 2002-08-05 2004-03-04 Oce Technol Bv 印刷システムにおける色の表現方法
US20030036085A1 (en) * 2002-08-19 2003-02-20 Salinaro Richard F Membranes
US20040043508A1 (en) * 2002-09-03 2004-03-04 Frutos Anthony G. Polymer-coated substrates for binding biological molecules
US20040081886A1 (en) * 2002-10-25 2004-04-29 David Zuckerbrod Separator for electrochemical devices
US20040137608A1 (en) * 2002-11-27 2004-07-15 Aaron Garzon Chemical microarrays and method for constructing same
KR100994566B1 (ko) * 2003-01-20 2010-11-15 삼성전자주식회사 고정화 영역을 갖는 포토레지스트 막을 포함하는 어레이장치 및 이를 이용한 표적 물질 검출방법
US20040152081A1 (en) * 2003-01-31 2004-08-05 Leproust Eric M. Viscosity control during polynucleotide synthesis
JP4098159B2 (ja) * 2003-05-28 2008-06-11 オリンパス株式会社 アクチュエータ駆動装置
TWI454465B (zh) 2003-06-03 2014-10-01 Melinta Therapeutics Inc 聯芳基雜環化合物及製法及其用途
US20050064431A1 (en) * 2003-09-09 2005-03-24 Eastman Kodak Company Biological microarray comprising polymer particles and method of use
US20050079506A1 (en) * 2003-10-09 2005-04-14 Eastman Kodak Company Filled, biological microarray and method for use
US20050095602A1 (en) * 2003-11-04 2005-05-05 West Jason A. Microfluidic integrated microarrays for biological detection
EP1689457A2 (en) * 2003-11-10 2006-08-16 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7323347B2 (en) * 2004-05-27 2008-01-29 Sensata Technologies, Inc. Biosensor surface structures and methods
KR101159071B1 (ko) * 2005-01-14 2012-06-26 삼성전자주식회사 신규한 히드로겔 공중합체, 상기 공중합체가 코팅되어있는 기판, 상기 공중합체를 이용하여 마이크로어레이를제조하는 방법 및 그에 의하여 제조된 마이크로어레이

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000269A2 (de) * 2001-06-22 2003-01-03 Bayer Aktiengesellschaft Neue verwendung für pde 10a-inhibitoren
WO2003093499A2 (en) * 2002-05-03 2003-11-13 Pfizer Products Inc. Therapeutic use of selective pde10 inhibitors
WO2005120514A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions

Also Published As

Publication number Publication date
AU2005323794A1 (en) 2006-07-13
CA2592986A1 (en) 2006-07-13
CA2592986C (en) 2011-02-15
AR052863A1 (es) 2007-04-11
CN102491969A (zh) 2012-06-13
PL1841757T3 (pl) 2010-10-29
ES2346674T3 (es) 2010-10-19
JP2008526825A (ja) 2008-07-24
RS51385B (sr) 2011-02-28
UY29324A1 (es) 2006-08-31
AU2005323794B2 (en) 2012-07-19
ZA200705427B (en) 2008-09-25
US7825254B2 (en) 2010-11-02
US20080214607A1 (en) 2008-09-04
HRP20100461T1 (hr) 2010-11-30
SV2008002365A (es) 2008-02-08
KR20070091005A (ko) 2007-09-06
KR100896380B1 (ko) 2009-05-08
NO340476B1 (no) 2017-05-02
UA86283C2 (uk) 2009-04-10
JP4302762B2 (ja) 2009-07-29
CR9180A (es) 2007-07-04
CY1110746T1 (el) 2015-06-10
CU20070156A7 (es) 2009-03-16
NO20072918L (no) 2007-07-05
HN2006000668A (es) 2010-09-17
WO2006072828A3 (en) 2006-11-09
DE602005022115D1 (de) 2010-08-12
AP2007004043A0 (en) 2007-06-30
GEP20094623B (en) 2009-02-25
EA200701252A1 (ru) 2007-12-28
IL183851A0 (en) 2007-10-31
NL1030863C2 (nl) 2006-12-28
CN101098866A (zh) 2008-01-02
EA012211B1 (ru) 2009-08-28
ATE472543T1 (de) 2010-07-15
PT1841757E (pt) 2010-08-31
MY142052A (en) 2010-08-30
US20060154931A1 (en) 2006-07-13
EP1841757B1 (en) 2010-06-30
GT200600002A (es) 2006-08-01
CU23780B7 (es) 2012-02-15
PE20060873A1 (es) 2006-09-04
HK1167263A1 (zh) 2012-11-23
DK1841757T3 (da) 2010-09-13
EG25993A (en) 2012-11-28
TWI312682B (en) 2009-08-01
US7429665B2 (en) 2008-09-30
ME01142B (me) 2013-03-20
TW200637555A (en) 2006-11-01
BRPI0518508A2 (pt) 2008-11-25
CN102491969B (zh) 2015-08-19
MX2007008287A (es) 2007-09-07
EP1841757A2 (en) 2007-10-10
NL1030863A1 (nl) 2006-07-10
SI1841757T1 (sl) 2010-09-30
IL183851A (en) 2012-03-29
NZ555737A (en) 2010-01-29
MA29140B1 (fr) 2008-01-02
TNSN07258A1 (fr) 2008-12-31
WO2006072828A2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
AP2362A (en) Heteroaromatic quinoline compounds and their use as PDE10 inhibitors.
AP2507A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors.
HRP20181622T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
EG24774A (en) Quinoline derivatives as phosphodiesterase inhibitors.
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
IL190078A0 (en) Kinase inhibitors
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
ZA200801822B (en) Pyrazine derivatives and use as p13k inhibitors
ZA200801441B (en) p38MAP kinase inhibitors and methods for using the same
AU2006335108A8 (en) CETP inhibitors
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
IL179280A0 (en) Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL225653A0 (en) Homo- and hetero-cyclic compounds suitable as cetp inhibitors
ZA200708868B (en) 7-Amino alkylidenyl-heterocyclic quinolones and napthyridones
SI1943243T1 (sl) Inhibotorji kinaz
IL191932A0 (en) Hydroxyquinoline derivatives
AP2188A (en) Substituted quinolines and their use as mycobacterial inhibitors.
IL191628A0 (en) Alkylsulphonamide quinolines
AP2322A (en) Antibacterial quinoline derivatives.
GB0519969D0 (en) Quinoline compounds
GB0516967D0 (en) Inhibitors
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors